CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...